Document Detail

Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.
MedLine Citation:
PMID:  23381694     Owner:  NLM     Status:  Publisher    
Background:Standard treatment options are limited for the management of non-metastatic castration-resistant prostate cancer (CRPC). This study, part of the ENTHUSE (EndoTHelin A USE) phase III programme, evaluated the efficacy and safety of the oral specific endothelin (ET)(A) receptor antagonist zibotentan vs placebo in patients with non-metastatic CRPC (non-mCRPC).Methods:This was a multicentre, randomized, double-blind, phase III study. Patients (n=1421) with non-mCRPC and biochemical progression (determined by rising serum PSA levels) were randomized to receive zibotentan 10 mg or placebo once daily. Based on the lack of efficacy signal in another ENTHUSE phase III study, an interim analysis was performed to determine whether the study was likely to achieve the co-primary objectives of improved overall survival (OS) and progression-free survival (PFS).Results:Criteria for continuation of this study were not met. A total of 79 deaths and 293 progression events were recorded at final data cutoff. Zibotentan-treated patients did not significantly differ from placebo-treated patients for OS (hazard ratio (HR): 1.13; 95% confidence interval (CI): 0.73-1.76, P=0.589) or PFS (HR: 0.89; 95% CI: 0.71-1.12, P=0.330). The most commonly reported adverse events in zibotentan-treated patients were peripheral oedema (37.7%), headache (26.2%) and nasal congestion (24.9%); each occurred with >15% higher incidence than in the placebo group.Conclusions:This trial was terminated early because of failure at interim analysis of the efficacy data to meet the defined criteria for continuation. Owing to the absence of demonstrable survival benefits in the ENTHUSE clinical studies, zibotentan is no longer under investigation as a potential treatment for prostate cancer.Prostate Cancer and Prostatic Disease advance online publication, 5 February 2013; doi:10.1038/pcan.2013.2.
K Miller; J W Moul; M Gleave; K Fizazi; J B Nelson; T Morris; F E Nathan; S McIntosh; K Pemberton; C S Higano
Related Documents :
25129854 - Exosomal mir-1290 and mir-375 as prognostic markers in castration-resistant prostate ca...
9339204 - Cancer of the pyriform sinus: trends towards conservative treatment.
25041714 - Ototoxicity evaluation in medulloblastoma patients treated with involved field boost us...
23232554 - Evaluation of lymph node metastasis in patients with gastric cancer: a comparison of th...
7956584 - Comparison of double and single parameters in dna analysis for staging and as a prognos...
6401594 - A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus ad...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-2-05
Journal Detail:
Title:  Prostate cancer and prostatic diseases     Volume:  -     ISSN:  1476-5608     ISO Abbreviation:  Prostate Cancer Prostatic Dis.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-2-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9815755     Medline TA:  Prostate Cancer Prostatic Dis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Urology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low P...
Next Document:  Measuring symptoms in localized prostate cancer: a systematic review of assessment instruments.